martes, 10 de julio de 2018

3HP for Latent TB Infection Treatment | 2018 | Newsroom | NCHHSTP | CDC

3HP for Latent TB Infection Treatment | 2018 | Newsroom | NCHHSTP | CDC

MedlinePlus

This graphic is summarizes CDC’s updated recommendations for the use of the short-course combination regimen of once-weekly isoniazid-rifapentine for 12 weeks (3HP) for treatment of latent tuberculosis (TB) infection. The updated recommendations include the use of 3HP: 1)In children and adolescents, 2-11 years old 2) In persons with latent TB infection who are living with HIV/AIDS and taking antiretroviral medications with acceptable drug interactions with rifapentine, and 3) by directly observed therapy or self-administered therapy in persons over 2 years of age.

New on the MedlinePlus Tuberculosis page:
CDC Releases Updated Recommendations for Treatment of Latent TB Infection
07/09/2018 10:06 AM EDT

Source: Centers for Disease Control and Prevention
Publicado por en

No hay comentarios:

Publicar un comentario

Suscribirse a: Enviar comentarios (Atom)